 In a note to clients on August 20, Canaccord Genuity analysts reiterated their Buy rating and 9 target price on shares of Zynerba Pharmaceuticals Inc, saying ZYNE stock presents a potentially significant opportunity for patient and risk-tolerant investors. Zynerba announced recently that it reached an agreement with the US Food and Drug Administration FDA on a path forward for Zygel synthetic transdermal cannabidiol gel in Fragile X syndrome FXS. 